Charlemagne Magna MENA R EUR
Managed by
Akhilesh Baveja
Akhilesh Baveja is the lead portfolio adviser for Charlemagne Capital’s MENA strategies with responsibility for researching companies operating across the Gulf and wider Middle East. He joined the group in 2011 after two years at GLG Partners, where he specialised in Saudi Arabian equities. He was previously employed as a senior analyst at Al-Rajhi Financial Services in Riyadh, having earlier spent four years at Unit Trust of India. He holds a Master of Management Science in Finance.
Objective
The Investment Objective of the Fund is to achieve capital growth by investing in the securities of the MENA (Middle East and North Africa) region. The MENA region presents significant opportunities to investors, as capital markets widen and deepen over time in an economically diverse area New vehicle, UCITS III structure with daily trading.
Performance
-
Rank 2/52 Total Return
-
Rank 43/52 Standard Deviation
-
Rank 30/52 Max Drawdown
| Fund Name | Currency | Return | |
|---|---|---|---|
| 1 | Lazard MENA Inst USD Acc | USD | 29.4% |
| 2 | Charlemagne Magna MENA R EUR | USD | 28.0% |
| 3 | T Rowe Middle East & Africa Equity I USD | USD | 21.6% |
| 4 | Deka-Global ConvergenceAktien CF | USD | 20.3% |
| 5 | QIC GCC Equity B USD | USD | 19.4% |
| View full league table | |||
| Fund Name | Currency | Risk | |
|---|---|---|---|
| 41 | Makaseb Arab Tigers MATF | USD | 10.6 |
| 42 | KAMCO GCC Opportunistic Fund | USD | 10.8 |
| 43 | Charlemagne Magna MENA R EUR | USD | 10.9 |
| 44 | Tharwa Islamic | USD | 10.9 |
| 45 | VTWM Special Funds - Middle East Equity USD | USD | 11.0 |
| View full league table | |||
| Fund Name | Currency | Loss | |
|---|---|---|---|
| 28 | Ashmore SICAV Middle East Equity I USD Acc | USD | -5.0% |
| 29 | EFG-Hermes Middle East & Developing Africa (MEDA) | USD | -5.0% |
| 30 | Charlemagne Magna MENA R EUR | USD | -5.1% |
| 31 | Al Mal MENA Equity | USD | -5.2% |
| 32 | Emirates MENA High Income USD A Acc | USD | -5.3% |
| View full league table | |||
Total Return
Quarterly Performance
| to 30/06/2017 | Annual | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|---|
| 2017 | 9.0% | 12.3% | |||
| 2016 | 12.7% | -1.4% | 8.7% | -6.0% | 11.9% |
| 2015 | 0.6% | 4.9% | 8.7% | -7.8% | -4.3% |
| 2014 | 22.4% | 18.4% | 2.2% | 18.5% | -14.7% |
| 2013 | 42.2% | 8.8% | 7.4% | 11.2% | 9.4% |
| 2012 | 7.7% | 13.5% | -8.3% | 3.3% | 0.3% |
| 2011 | 2.1% | -9.7% | 2.4% |
Month by Month Performance
Returns Vs Risk
Asset Allocation
Breakdown
Top 10 Holdings
| Stock | Size |
|---|---|
| NMC Health PLC ORD | 10.29 |
| Human Soft Holding Company KSCP ORD | 9.75 |
| Morgan Stanley BV 0.000% 01-Aug-2017 | 5.42 |
| Al Rajhi Bank/HSBC Bank PLC Participatory Note | 4.42 |
| DALLAH /CREDIT S | 4.37 |
| Emirates NBD Bank PJSC ORD | 3.79 |
| THE CO./JPMOSTPR | 3.72 |
| Morgan Stanley BV 0.000% 08-Jan-2018 | 3.58 |
| EFG Hermes Holdings SAE ORD | 3.56 |
| Aramex PJSC ORD | 3.48 |
Registered For Sale In
- Austria
- Denmark
- France
- Germany
- Ireland
- Luxembourg
- Netherlands
- Switzerland
Fund Info
- Launch date22/02/2011
- Share Class size30Mn
- Base currencyEUR
-
ISIN IE00B3NMJY03
Purchase Info
- Min. initial investment5,000
- Min. regular additional investment0
Charges
- Annual management1.95%